Completed PHASE2 INTERVENTIONAL NCT00026819

Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction

Pre-Emptive Analgesic Effects of a Selective COX-2 Inhibitor (Rofecoxib) in the Oral Surgery Model

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)

Conditions Pain

Interventions Rofecoxib

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Nov 30, 2001 Completion: Nov 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00026819, this PHASE2 trial focuses on Pain and remains completed. Sponsored by National Institute of Dental and Craniofacial Research (NIDCR), it has been updated 5 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Dental and Craniofacial Research (NIDCR)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States